Biopharmaceutical company focused on developing targeted therapies for cancer.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing targeted therapies for patients with cancer. The company focuses on creating innovative treatments designed to address the limitations of existing cancer therapies. Its lead product candidates are NVL-520 and NVL-655, both of which are brain-penetrant inhibitors designed to overcome resistance mechanisms in cancer treatment.
NVL-520 is a ROS1-selective inhibitor that targets ROS1 fusions expressing the normal ROS1 kinase domain, without any drug-resistant mutations. This candidate is designed to remain effective even in the presence of mutations that confer resistance to both approved and investigational ROS1 inhibitors. NVL-520 is currently under Phase I development.
NVL-655 is an ALK-selective inhibitor aimed at addressing the clinical challenges posed by emergent treatment resistance, central nervous system-related adverse events, and brain metastases. This inhibitor seeks to provide a solution where first-, second-, and third-generation ALK inhibitors may fall short. NVL-655 is undergoing Phase I/II clinical trials.
Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent, Inc. continues to advance its pipeline of targeted cancer therapies. The company's innovative approach aims to provide new hope for patients facing difficult-to-treat cancers by focusing on precision medicine and overcoming resistance mechanisms.